May 10, 2012
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
ACS medicinal chemistry letters
- Volume
- 3
- Number
- 5
- First page
- 427
- Last page
- 32
- Language
- English
- Publishing type
- Research paper (scientific journal)
- DOI
- 10.1021/ml300055n
- Publisher
- AMER CHEMICAL SOC
Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects. Here we introduce a novel RXR partial agonist CBt-PMN (11b), which shows a potent glucose-lowering effect and improvements of insulin secretion and glucose tolerance without the serious adverse effects caused by RXR full agonists. We suggest that RXR partial agonists may be a new class of antitype 2 diabetes drug candidates.
- Link information
-
- DOI
- https://doi.org/10.1021/ml300055n
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/24900488
- PubMed Central
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025743
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000303786400017&DestApp=WOS_CPL
- ID information
-
- DOI : 10.1021/ml300055n
- ISSN : 1948-5875
- Pubmed ID : 24900488
- Pubmed Central ID : PMC4025743
- Web of Science ID : WOS:000303786400017